Zobrazeno 1 - 10
of 358
pro vyhledávání: '"Craig T Jordan"'
Autor:
Nazmul Islam, Jamie S Reuben, Justin Dale, James W Coates, Karan Sapiah, Frank R Markson, Craig T Jordan, Clay Smith
Publikováno v:
JMIR Cancer, Vol 10, p e54740 (2024)
BackgroundThe treatment of acute myeloid leukemia (AML) in older or unfit patients typically involves a regimen of venetoclax plus azacitidine (ven/aza). Toxicity and treatment responses are highly variable following treatment initiation and clinical
Externí odkaz:
https://doaj.org/article/c7f1cc1779ca40a9bdd9fb999aeb7eef
Autor:
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Austin Gillen, Krysta Engel, Stephanie Gipson, Monica Ransom, Maria Amaya, Anagha Inguva, Maura Gasparetto, Mark J. Althoff, Regan Miller, Ian Shelton, Hunter Tolison, Anna Krug, Rachel Culp-Hill, Angelo D’Alessandro, Daniel W Sherbenou, Daniel A. Pollyea, Clayton Smith, Craig T Jordan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The treatment of blast phase chronic myeloid leukemia (bpCML) remains a challenge due at least in part to drug resistance of leukemia stem cells (LSCs). Recent clinical evidence suggests that the BCL-2 inhibitor venetoclax in combination with ABL-tar
Externí odkaz:
https://doaj.org/article/1e698dc2b5034f73b534561525fe0273
Autor:
Maria Amaya, Christine Mcmahon, Jonathan Aaron Gutman, Marc Schwartz, Brett Sevens, Connor Sohalski, Jennifer Tobin, Clayton Smith, Craig T Jordan, Daniel Aaron Pollyea
Publikováno v:
HemaSphere, Vol 7, p e95778ba (2023)
Externí odkaz:
https://doaj.org/article/51e1c577cf504e6fa7f5e47e3ec7d7f7
Autor:
Hae J Park, Mark A Gregory, Vadym Zaberezhnyy, Andrew Goodspeed, Craig T Jordan, Jeffrey S Kieft, James DeGregori
Publikováno v:
eLife, Vol 11 (2022)
While leukemic cells are susceptible to various therapeutic insults, residence in the bone marrow microenvironment typically confers protection from a wide range of drugs. Thus, understanding the unique molecular changes elicited by the marrow is of
Externí odkaz:
https://doaj.org/article/ea84268fcc014d5baa026f0532c4b188
Autor:
Shuqian Liu, Sumitra Miriyala, Mignon A Keaton, Craig T Jordan, Christina Wiedl, Daret K St Clair, Jeffrey A Moscow
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85702 (2014)
Thiamine-dependent enzymes (TDEs) control metabolic pathways that are frequently altered in cancer and therefore present cancer-relevant targets. We have previously shown that the recombinant enzyme thiaminase cleaves and depletes intracellular thiam
Externí odkaz:
https://doaj.org/article/f79d5967ecbf4b308fbfbda866487bd0
Autor:
Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernan Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A Zweidler-McKay, Dario Campana, Gautam Borthakur, Carlos Bueso-Ramos, Elizabeth Shpall, Deborah A Thomas, Craig T Jordan, Hagop Kantarjian, William R Wilson, Richard Lock, Michael Andreeff, Marina Konopleva
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e23108 (2011)
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell survival and confer resistance to anti-leukemic drugs. There is evidence that BM microenvironment contains hypoxic areas
Externí odkaz:
https://doaj.org/article/8a8e56495e7d49b3a2d1a39503f27346
Autor:
Jolanta Skalska, Paul S Brookes, Sergiy M Nadtochiy, Shannon P Hilchey, Craig T Jordan, Monica L Guzman, Sanjay B Maggirwar, Margaret M Briehl, Steven H Bernstein
Publikováno v:
PLoS ONE, Vol 4, Iss 12, p e8115 (2009)
There has been much interest in targeting intracellular redox pathways as a therapeutic approach for cancer. Given recent data to suggest that the redox status of extracellular protein thiol groups (i.e. exofacial thiols) effects cell behavior, we hy
Externí odkaz:
https://doaj.org/article/b1a7001c5f124595b9ee8e68e7704479
Autor:
Deepak M. Sahasrabudhe, Jane L. Liesveld, Mohammad Minhajuddin, Niloy A. Singh, Subhangi Nath, Vishuwes M. Kumar, Marlene Balys, Andrew G. Evans, Mitra Azadniv, Jeanne N. Hansen, Michael W. Becker, Ashoke Sharon, V Kaye Thomas, Richard G. Moore, Manoj K. Khera, Craig T. Jordan, Rakesh K. Singh
Acute myeloid leukemia (AML) is fatal in majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that immunization of rabbits with normal peripheral W
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ee01317ad26d762b135d4f4bdf96ec5
https://doi.org/10.21203/rs.3.rs-2793643/v1
https://doi.org/10.21203/rs.3.rs-2793643/v1
Autor:
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea
Publikováno v:
Haematologica.
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary. We designed a clinical trial to investigat
Autor:
Christopher C. Porter, Rajeev Vibhakar, Sujatha Venkataraman, Craig T. Jordan, Chengjing Zhou, Susan P. Fosmire, Lori Gardner, Dmitry Baturin, Jonathan C. Snedeker, Tamara B. Garcia
Cell cycle analysis of acute leukemia cells treated with olaparib and AZD1775. A. The indicated cell lines were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. Results are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e651a5c472aeeb8cbabc76854f2f4b4
https://doi.org/10.1158/1535-7163.22508035.v1
https://doi.org/10.1158/1535-7163.22508035.v1